Sei Investments Co. cut its holdings in Perrigo Company plc (NYSE:PRGO – Free Report) by 2.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 368,281 shares of the company’s stock after selling 9,463 shares during the quarter. Sei Investments Co. owned 0.27% of Perrigo worth $9,469,000 as of its most recent SEC filing.
Other institutional investors have also recently added to or reduced their stakes in the company. Versant Capital Management Inc bought a new stake in shares of Perrigo in the 4th quarter valued at $45,000. GAMMA Investing LLC increased its stake in Perrigo by 93.7% in the fourth quarter. GAMMA Investing LLC now owns 1,920 shares of the company’s stock valued at $49,000 after purchasing an additional 929 shares in the last quarter. Central Pacific Bank Trust Division raised its holdings in shares of Perrigo by 33.3% during the fourth quarter. Central Pacific Bank Trust Division now owns 2,000 shares of the company’s stock valued at $51,000 after purchasing an additional 500 shares during the period. Venturi Wealth Management LLC boosted its position in shares of Perrigo by 97.8% during the 4th quarter. Venturi Wealth Management LLC now owns 4,215 shares of the company’s stock worth $108,000 after purchasing an additional 2,084 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Perrigo in the 4th quarter valued at about $149,000. 95.91% of the stock is owned by institutional investors and hedge funds.
Insider Activity
In related news, EVP Ronald Craig Janish sold 7,800 shares of the business’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $27.44, for a total value of $214,032.00. Following the transaction, the executive vice president now directly owns 33,666 shares of the company’s stock, valued at approximately $923,795.04. The trade was a 18.81 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.70% of the stock is currently owned by corporate insiders.
Wall Street Analyst Weigh In
Check Out Our Latest Stock Analysis on Perrigo
Perrigo Price Performance
PRGO stock opened at $28.06 on Monday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.77 and a current ratio of 2.56. The business has a 50-day simple moving average of $26.11 and a two-hundred day simple moving average of $26.15. The company has a market capitalization of $3.83 billion, a P/E ratio of -23.98 and a beta of 0.48. Perrigo Company plc has a 52-week low of $23.14 and a 52-week high of $33.46.
Perrigo (NYSE:PRGO – Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported $0.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.01. Perrigo had a positive return on equity of 7.38% and a negative net margin of 3.64%. The business had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.20 billion. Research analysts expect that Perrigo Company plc will post 2.56 EPS for the current fiscal year.
Perrigo Increases Dividend
The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 25th. Stockholders of record on Friday, March 7th were paid a $0.29 dividend. This represents a $1.16 dividend on an annualized basis and a dividend yield of 4.13%. The ex-dividend date was Friday, March 7th. This is an increase from Perrigo’s previous quarterly dividend of $0.28. Perrigo’s payout ratio is presently -92.80%.
About Perrigo
Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.
Further Reading
- Five stocks we like better than Perrigo
- What Are Dividend Challengers?
- Venezuelan Tariffs Could Power These 3 Diesel-Driven Winners
- Investing in Construction Stocks
- MarketBeat Week in Review – 03/24 – 03/28
- There Are Different Types of Stock To Invest In
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.